Novo Nordisk plans further significant investments to solve capacity issues
Novo Nordisk will once again ramp up investments in new production capacity in 2024, after there was strong sales growth of the GLP-1 molecule semaglutide in 2023 that the Danish pharmaceutical company could not keep up with demand.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.